Company news
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) news
Inovio Pharmaceuticals, Inc. news releases on 6ix. Latest, Nov 9, 2020: INOVIO Reports Third Quarter 2020 Financial Results
Press releases — page 4
INOVIO Reports Third Quarter 2020 Financial Results
November 8, 2020
INOVIO to Report Third Quarter 2020 Financial Results on November 9, 2020
October 25, 2020
INOVIO Reports FDA Partial Clinical Hold for Planned Phase 2 / 3 Trial of COVID-19 Vaccine Candidate INO-4800
September 27, 2020
INOVIO Adds Thermo Fisher Scientific To Global Manufacturing Consortium
September 7, 2020
INOVIO Reports Second Quarter 2020 Financial Results; Provides DNA Medicines Clinical Program Mid-Year Update
August 9, 2020
INOVIO's COVID-19 DNA Vaccine INO-4800 Provides Protection with Memory Immune Responses In Non-Human Primates Challenged with SARS-CoV-2 Virus
July 29, 2020
INOVIO Receives Orphan Drug Designation From U.S. FDA for DNA Medicine INO-3107 To Treat Rare Disease Recurrent Respiratory Papillomatosis (RRP)
July 28, 2020
INOVIO to Report Second Quarter 2020 Financial Results on August 10, 2020
July 26, 2020
INOVIO Announces Positive Interim Phase 1 Data For INO-4800 Vaccine for COVID-19
June 29, 2020
INOVIO Expands Senior Management Team
June 24, 2020
INOVIO Receives $71 Million Contract From U.S. Department of Defense To Scale Up Manufacture of CELLECTRA® 3PSP Smart Device and Procurement of CELLECTRA® 2000 for COVID-19 DNA Vaccine
June 22, 2020
INOVIO and IVI Partner with Seoul National University Hospital to Start Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine (INO-4800) in South Korea
June 3, 2020
INOVIO's COVID-19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models
May 19, 2020
INOVIO Reports First Quarter 2020 Financial Results; Provides Business Update
May 10, 2020
INOVIO Expands Manufacturing of COVID-19 DNA Vaccine INO-4800 With New Funding from CEPI
April 29, 2020
INOVIO Completes Enrollment in the Phase 1 U.S. Trial of INO-4800 for COVID-19 DNA Vaccine; Interim Results Expected in June
April 27, 2020
INOVIO to Report First Quarter 2020 Financial Results on May 11, 2020
April 26, 2020
IVI, INOVIO, and KNIH to Partner with CEPI in Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine in South Korea
April 15, 2020
INOVIO to Host its Annual Meeting of Stockholders in Virtual Format and at a New Time
April 14, 2020
INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today
April 5, 2020
INOVIO Interim Results of an Open-Label Phase 2 Trial of VGX-3100 Show Efficacy Against HPV-associated Vulvar Dysplasia
March 29, 2020
INOVIO Reports Positive Interim Phase 2 VGX-3100 Results In Patients with HPV-associated Anal Dysplasia
March 25, 2020
INOVIO Pharmaceuticals Reports 2019 Fourth Quarter and Year-End Financial Results
March 11, 2020
Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800
March 2, 2020
Inovio Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
March 1, 2020
Inovio Receives Authorization from the U.S. FDA To Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine To Treat a Rare Disease -- Recurrent Respiratory Papillomatosis (RRP)
February 9, 2020
Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China
January 29, 2020
Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus
January 22, 2020
Inovio Welcomes Biotech Leader to its Board of Directors
January 14, 2020
Inovio Provides Update on Clinical Program Plans for 2020
January 5, 2020
Inovio Pharmaceuticals Reports 2019 Third Quarter Financial Results
November 11, 2019
Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab)
November 4, 2019
Inovio Receives NIH Funding to Target its dMAb® Technology Against Antimicrobial-Resistant Infection
September 16, 2019
Inovio Completes Enrollment of its VGX-3100 Open-label Phase 2 Trial for Treatment of HPV-Related High-Grade Anal Dysplasia
August 18, 2019
Inovio Pharmaceuticals Reports 2019 Second Quarter Financial Results
August 7, 2019
Inovio Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 8, 2019
July 29, 2019
Inovio Sharpens Focus On HPV-Related Diseases And Fast-to-Market Product Candidates
July 15, 2019
Inovio Completes Enrollment of VGX-3100 Phase 2 Trial for the Treatment of HPV-Related Vulvar Dysplasia (VIN)
July 7, 2019
Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer
June 25, 2019
Inovio Receives $8.14 Million Award to Support Further Development of its Commercial Skin Delivery Device
June 9, 2019
Inovio and QIAGEN Establish Collaboration to Develop Diagnostic Test for VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer
May 15, 2019
Inovio and Plumbline Life Sciences Establish Animal Health Collaboration to Develop A Novel Vaccine Against Deadly African Swine Fever Virus
May 14, 2019
Inovio Receives European Medicines Agency Certification For Quality and Non-Clinical Data for Its Phase 3 Product, VGX-3100
May 5, 2019
Inovio Pharmaceuticals to Report First Quarter 2019 Financial Results on May 9, 2019
April 30, 2019
Inovio Achieves Third Cancer Indication Milestone for MEDI0457 Phase 2 Development
April 7, 2019
Inovio's Novel HPV Therapy INO-3106 Demonstrates Clinical Efficacy Against Rare Respiratory Tract Tumors in Pilot Clinical Study
April 2, 2019
Inovio Presents Cancer Killing Data of Its Transformative DNA-Encoded Bi-specific T Cell Engagers (dBiTEs) at AACR
April 1, 2019
Inovio Completes Enrollment Ahead of Schedule In Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron's PD-1 Inhibitor
March 31, 2019